Is α/β for breast cancer really low?

Area of Science:

• Radiation oncology
• Medical physics
• Cancer biology

Background:

• The alpha/beta (α/β) ratio is a critical radiobiological parameter influencing radiotherapy fractionation.
• A low α/β ratio in breast cancer suggests potential benefits from hypofractionated treatment schedules.
• Exploring hypofractionation for breast cancer requires robust estimation of its α/β ratio.

Purpose of the Study:

• To confirm the low α/β ratio in breast cancer using data from large randomized clinical trials.
• To provide evidence supporting the exploration of hypofractionated radiotherapy for breast cancer treatment.

Main Methods:

• Developed a generalized linear-quadratic (LQ) model incorporating Poisson statistics to predict disease-free survival.
• Fitted outcome data from early-stage breast radiotherapy trials to estimate LQ model parameters.
• Validated the model and parameters using data from surgery-alone and radiotherapy-alone treatments.

Main Results:

• Estimated population-averaged radiobiologic parameters for breast cancer: α/β = 2.88 Gy (95% CI: 0.75-5.01), α = 0.08 ± 0.02 Gy⁻¹, and T(d) = 14.4 ± 7.8 days.
• Analysis of radiation-alone data yielded an α/β ratio of 3.89 ± 6.25 Gy, confirming a low α/β ratio.
• Proposed equivalent hypofractionation regimens, including 2.26 Gy × 20 and 3.34 Gy × 10.

Conclusions:

• Clinical data analysis from multiple institutions supports a low α/β ratio for breast cancer.
• The findings encourage the adoption of hypofractionated radiotherapy regimens for breast cancer treatment.
• This research validates the radiobiological basis for optimizing breast cancer irradiation.